GlassScriptPhysician profile
Suthep Arora
NPI 1750564068
$1,946.75
in general payments reported to CMS, 2019-2025
14 companies · $566 in 2025
The $566 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.30 · 2020: $243 · 2021: $44.90 · 2022: $241 · 2023: $319 · 2024: $484 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,344 · Education: $24.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,344.01 |
| Education | $24.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $359.44 | 2022-2025 | Avycaz |
| Gilead Sciences, INC. | $231.34 | 2020-2025 | Veklury |
| Viiv Healthcare Company | $221.30 | 2022-2025 | Cabenuva, Apretude, Rukobia |
| Melinta Therapeutics, LLC | $177.92 | 2020-2025 | Rezzayo, Kimyrsa, Vabomere |
| Merck Sharp & Dohme LLC | $172.02 | 2020-2025 | Pifeltro, Zerbaxa, Delstrigo |
| Allergan, INC. | $169.83 | 2019-2020 | |
| Astellas Pharma US INC | $143.15 | 2023-2025 | Cresemba |
| Insmed, INC. | $130.68 | 2020-2025 | Arikayce |
| Ferring Pharmaceuticals INC. | $128.87 | 2022-2023 | Rebyota |
| Shionogi INC | $84.47 | 2021-2025 | Fetroja |
| Janssen Biotech, INC. | $43.51 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $31.39 | 2024-2025 | Vowst |
| Cumberland Pharmaceuticals, INC. | $29.34 | 2024-2025 | Vibativ |
| La Jolla Pharmaceutical Company | $23.49 | 2024 | Xacduro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suthep Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.